CN Patent

CN102076852A — 因子7表达的调节

Assigned to Ionis Pharmaceuticals Inc · Expires 2011-05-25 · 15y expired

What this patent protects

本文公开了用于对有需要的个体减少因子7和治疗或预防血栓并发症、过度增生病症或发炎症状的反义化合物和方法。可以通过给药以靶向因子7的反义化合物来改善的疾病症状包括血栓症、栓塞和血栓栓塞，例如，深静脉血栓、肺栓塞、心肌梗塞、中风、癌症、风湿性关节炎和纤维化。

USPTO Abstract

本文公开了用于对有需要的个体减少因子7和治疗或预防血栓并发症、过度增生病症或发炎症状的反义化合物和方法。可以通过给药以靶向因子7的反义化合物来改善的疾病症状包括血栓症、栓塞和血栓栓塞，例如，深静脉血栓、肺栓塞、心肌梗塞、中风、癌症、风湿性关节炎和纤维化。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN102076852A
Jurisdiction: CN
Classification: —
Expires: 2011-05-25
Drug substance claim: No
Drug product claim: No
Assignee: Ionis Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.